New Technology– category –
-
Generate Biomedicines’ AI-Designed Antibody GB-0895 Advances to Global Phase 3 for Severe Asthma; Insilico Medicine’s IPF Drug also Reaches Phase 3
Stock Titan USA Overview Generate Biomedicines announced its AI-designed anti-TSLP monoclonal antibody, GB-0895, has advanced to global Phase 3 clinical trials for severe asthma, highlighted in its Q2 2026 financial results. Novartis has... -
AI Drug Discovery Faces New Pain Points: Chemical Models Deliver Results, While Biological Models Struggle to Cross the ‘Valley of Death’
Moomoo USA Overview In AI-driven drug discovery, chemical models have successfully accelerated R&D by efficiently identifying targets and generating novel molecular structures. However, advancements in biological models still need to... -
AI Drug Discovery’s Core Challenge: Not Data Volume, But Converting Data into Actionable Clinical Evidence
MedCity News USA Overview The real challenge in AI-driven drug discovery is not the abundance of data, but the ability to transform that data into meaningful 'evidence' while preserving clinical context. Robust scientific and regulatory ... -
Insilico Medicine and Saudi Aramco Unveil sorbaMOF DB to Accelerate AI-Driven MOF Discovery for DAC Technologies
Unibest Industrial Co., Ltd. International Overview Insilico Medicine, in collaboration with Saudi Aramco, has launched 'sorbaMOF DB,' a validated materials database with an interpretable AI framework designed to accelerate the discovery... -
AI Biotechs Drive ‘Fail-Fast’ Drug Development in Biopharma, Powered by DeepMind’s AlphaFold
BioSpace USA Overview AI-centric biotechs like Isomorphic Labs and Generate Biomedicines are leveraging Google DeepMind's AlphaFold and proprietary 'dataverses' to propel a 'fail-fast' approach in drug discovery through in silico experim... -
AI-Driven CRISPR Design: Revolutionizing Gene Editing with Enhanced Precision and Efficiency
Preprints.org International Overview A comprehensive review systematically investigates AI-driven tools and methodologies for CRISPR design, highlighting AI's role in significantly enhancing gene editing precision, efficiency, and automa... -
AI Compresses Drug Discovery Timelines from Years to Months, Insilico Medicine’s IPF Drug Advances to Phase 2 in 18 Months
MarketScale USA Overview Generative AI is dramatically shortening drug discovery timelines, reducing development from years to months. Insilico Medicine's platform successfully advanced a candidate compound for idiopathic pulmonary fibro... -
Isomorphic Labs: AI-Designed Drugs Head to Human Trials, Reshaping Pharma’s Future
Wired USA Overview Isomorphic Labs, a Google DeepMind spin-off, is on the verge of commencing human clinical trials for drugs entirely designed by artificial intelligence. Leveraging its foundational AlphaFold system, the company aims to... -
bioRxiv Unveils Joint Transcriptomic and Morphological Phenotype Modeling for Generative Molecular Design
bioRxiv International Overview A bioRxiv preprint details research on jointly modeling transcriptomic and morphological phenotypes for generative molecular design. This novel approach allows for the simultaneous consideration of gene exp... -
CAi Copilot Leverages Agentic AI for Intent-Driven Molecular Design, Reducing Operational Burden
arXiv USA Overview CAi Copilot introduces an agentic workflow system that translates researchers' intent into adaptive and traceable molecular computations, aiming to significantly reduce operational workload in early-stage molecular des...
